Skip to main content
BMRNBioMarin Pharmaceutical Inc.Sell5.4·$66.92-0.07%

BioMarin Pharmaceutical (BMRN) Q2 2026 earnings — TrendMatrix coverage

BEAT+26.6% vs estimateEPS $1.20 vs $0.95 estVerdict Buy (Wait)Hold

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$1.20
Estimate
$0.95
Surprise
+26.6%
Revenue (period 2026-06-30)
$989.7M
Score at report (before → after)
5.45.6/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

BioMarin Pharmaceutical (BMRN) beat the $0.95 estimate with diluted EPS of $1.20 — a large 26.6% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.4/10) to Hold at 5.6/10 after the report.

Current read · as of 2026-09-04

Where TrendMatrix's rating stands now

TrendMatrix currently rates BMRN Sell at 5.4/10.

1 of the last 4 quarters beat the estimate; this quarter's +26.6% surprise compares with a -18.1% four-quarter average. Next scheduled report: 2026-10-26.

What supports the rating

  • Sector modifier (Healthcare): +0.5
  • Analyst upside: 24%

What argues against it

  • Concentration risk — Customer: Sanofi
  • Concentration risk — Supplier: sole source raw material suppliers
  • Consecutive earnings misses (3)

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$66.92
Price target
$82.28
Stop
$63.03
Upside to target
+23.0%
Reward-to-risk
3.8:1

The stock trades at 179.5× trailing but 10.2× forward earnings — consensus estimates already build in a substantial earnings recovery.

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare context

BMRN at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Biotechnology
Market cap
$12.86B
P/E (fwd)
10.2
P/E (ttm)
179.5
52-week range
$49.26$70.98
Off 52-week high
5.7%
RSI (14)
47
Volume vs avg
0.66×
Score today
5.4/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks BMRN Earnings Q2 2026 earnings